Aptevo Therapeutics (NASDAQ:APVO) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Fidelity Earnings reports. The business had revenue of $9.01 million for the quarter, compared to the consensus estimate of $8.05 million. Aptevo Therapeutics had a negative net margin of 195.98% and a negative return on equity of 148.97%.
Shares of Aptevo Therapeutics stock traded up $0.04 on Friday, reaching $0.65. The company had a trading volume of 727,500 shares, compared to its average volume of 519,858. The firm’s 50 day moving average price is $0.61 and its two-hundred day moving average price is $0.75. The firm has a market cap of $29.33 million, a PE ratio of -0.27 and a beta of 2.44. Aptevo Therapeutics has a 52-week low of $0.49 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.21 and a current ratio of 2.63.
A number of research firms have recently issued reports on APVO. Piper Jaffray Companies reduced their price target on shares of Aptevo Therapeutics from $4.50 to $3.00 in a research note on Friday, October 4th. ValuEngine raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Zacks Investment Research downgraded shares of Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 16th.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.
Recommended Story: Systematic Risk and Investors
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.